Practice

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 22nd 2020

By Tony Hagen

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Webinar: Choice Is Vital to Biosimilar Savings Picture

July 21st 2020

By Tony Hagen

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16th 2020

By Tony Hagen

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.

In Search of Better Algorithms for Treatment of Crohn Disease

July 16th 2020

By Deana Ferreri, PhD

Wide variation in treatment patterns for Crohn disease is attributable to failures to translate evidence uniformly and cost barriers. Authors of a new report have formulated algorithms to help reduce heterogeneity in treatment of patients.

Biosimilar Awareness Week Proves Successful for Australia

July 14th 2020

By Skylar Jeremias

The Generic and Biosimilar Medicines Association in Australia reported its 2020 Biosimilar Awareness Week was successful, with educational messages from the event reaching over 540,000 Australians via social media.

Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization

July 12th 2020

We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.

Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer

July 10th 2020

By Skylar Jeremias

A phase 1b/2 trial evaluating a trastuzumab biosimilar as part of a first-line triplet regimen demonstrated significant tumor shrinkage in HER2-positive advanced gastric cancer.

Use of Infliximab Biosimilar in Medicare Population Is Low but Growing

July 7th 2020

By Deana Ferreri, PhD

Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.

Review: Nurses Can Play Key Role in Improving Biosimilar Use

July 7th 2020

By Skylar Jeremias

A review laid out ways for nurses to address patients’ questions on biosimilars in order to help them take on the role of improving utilization rates in cancer treatment.

Study of Neupogen vs Biosimilars Draws Fire

July 6th 2020

By Tony Hagen

After a study from India suggested a higher incidence of adverse reactions in patients using biosimilar filgrastims, 2 European biosimilar consultants and oncologists raised objections to the study’s methodology.